Key Highlights
● Tectonic's TX2100 was generally safe and well tolerated in a Phase 1a trial of 48 healthy volunteers.
● The company reports no deaths, serious adverse events or severe treatment-emergent adverse events at any dose in the trial.
● The FDA cleared the IND for TX2100 in HHT in August 2026 and granted Fast Track Designation in September.
● An open-label Phase 1b trial is planned by year-end 2026, with a placebo-controlled Phase 2 trial expected in early 2027.
Tectonic Therapeutic, Inc. (NASDAQ:TECX) reported that its experimental antibody TX2100 was generally safe and well tolerated in a Phase 1a trial in healthy volunteers, with no deaths or serious adverse events. The company also said in a Form 8-K on September 29, 2026 that the FDA granted Fast Track designation to TX2100 for hereditary hemorrhagic telangiectasia (HHT) and cleared its Investigational New Drug application, allowing a Phase 1b trial that the company plans to start by the end of 2026. The report was made under Item 8.01, Other Events, with a press release attached as Exhibit 99.1.
The Phase 1a Results
According to the release, the Phase 1a study was a randomized, double-blind, placebo-controlled single ascending dose trial in 48 healthy adult volunteers aged 18 to 55. Participants were divided into six cohorts of eight and randomized 3 to 1 to TX2100 or placebo. Doses ranged from 0.1 mg/kg intravenous to 600 mg subcutaneous. A separate multiple-dose part enrolled six volunteers. The trial was conducted at CMAX Clinical Research in Adelaide, Australia.
The company reports that treatment-emergent adverse events were mild or moderate and transient, with no deaths, serious adverse events or severe treatment-emergent adverse events at any dose, and no clinically significant changes in vital signs, laboratory values or electrocardiograms. Anti-drug antibody results were still pending. The pharmacokinetic data showed target-mediated drug disposition at low concentrations, which the company says is consistent with strong binding to the target. A trial in healthy volunteers is designed mainly to assess safety; it does not measure whether the drug works in patients.
The Regulatory Steps
The release states that the FDA cleared the IND for TX2100 in HHT in August 2026 and granted Fast Track designation in September 2026. Fast Track is a program meant to facilitate development and expedite review of drugs for serious conditions with unmet medical needs. It does not mean the drug is approved or will be. The company plans an open-label Phase 1b trial in HHT patients who depend on hematologic support, looking at endpoints such as iron and red blood cell support needs and hematologic parameters, to start by year-end 2026. A placebo-controlled Phase 2 trial in moderate-to-severe HHT, with endpoints including epistaxis, hemoglobin and hematologic support, is expected to start in early 2027, and the two trials are planned to run in parallel.
The Drug and the Disease
TX2100 is described as a VHH-Fc fusion antagonist antibody that binds the APJ receptor, which mediates signaling by the pro-angiogenic hormone apelin. The company says the target is mostly found on endothelial cells and is upregulated during pathologic angiogenesis, and that APJ antagonism showed activity in multiple preclinical HHT models.
The release describes HHT as a rare inherited vascular disorder affecting approximately 75,000 people in the United States and the second most common inherited bleeding disorder. It says no therapies are approved and that fragile blood vessels cause recurrent bleeding, chronic anemia and, for some patients, arteriovenous malformations in organs such as the lungs, brain and liver.
Chief Executive Officer Alise Reicin, M.D., is quoted as saying: "We are very excited about our TX2100 clinical program as a potential first-in-class, selective anti-angiogenic therapy for HHT, a disease with no approved treatments." Chief Medical Officer Marcella K. Ruddy, M.D., said the topline safety results "are consistent with TX2100's preclinical results."
TX2100 Phase 1b Start Set for Year-End
The nearest milestone is the start of the Phase 1b trial by year-end 2026, followed by the planned Phase 2 start in early 2027. Also outstanding are the anti-drug antibody results and full Phase 1a data.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...